temozolomide has been researched along with Carcinoma in 37 studies
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas that are resistant to other therapies." | 8.95 | Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. ( Ahmad, MM; Aldabas, BS; Aljoaib, NN; Almalki, MH; Alotaibi, MJ; Alshahrani, F; Wahedi, TS, 2017) |
| "Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas." | 8.88 | Temozolomide in aggressive pituitary adenomas and carcinomas. ( Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H, 2012) |
| "Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging." | 7.96 | Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. ( Bojunga, J; Buchfelder, M; Buslei, R; Deutschbein, T; Droste, M; Elbelt, U; Honegger, J; Johanssen, S; Knappe, UJ; Kolenda, H; Lammert, A; Micko, A; Petersenn, S; Ritzel, K; Schlaffer, SM; Strasburger, CJ; Topuzoglu-Müller, T; Unger, N; Vila, G, 2020) |
| "To evaluate the impact of temozolomide (TMZ) introduction on the survival of patients with pituitary carcinoma (PC) compared to aggressive pituitary adenoma (APA)." | 7.91 | Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. ( Aharon-Hananel, G; Badarna, M; Percik, R; Tirosh, A; Uri, I, 2019) |
| " Descriptions of aggressive pituitary tumors and pituitary carcinomas have increased notably over the last decade following the first report on the successful treatment of pituitary carcinomas using temozolomide." | 7.83 | Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. ( Lasolle, H; Raverot, G, 2016) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 7.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "Prolonged administration of adjuvant temozolomide is safe and can be favorable for patients with anaplastic gliomas." | 7.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment." | 7.77 | A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. ( Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K, 2011) |
| "Temozolomide treatment has a wide range of efficacy in patients with pituitary carcinoma or locally aggressive pituitary adenoma." | 7.76 | Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. ( Cangi, MG; Gill, AJ; Losa, M; Mazza, E; McCormack, A; Mortini, P; Motta, M; Reni, M; Talarico, A; Terreni, MR, 2010) |
| "Eight patients, five with pituitary carcinomas (three prolactin (PRL) and two ACTH) and three with aggressive pituitary tumors (one PRL and two ACTH), all treated with temozolomide administered orally for four to 24 cycles, were included in our French multicenter study." | 7.76 | Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. ( Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J, 2010) |
| "Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary tumors." | 7.01 | Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. ( Barbot, M; Bergo, E; Caccese, M; Ceccato, F; Cerretti, G; Lombardi, G; Occhi, G; Padovan, M; Scaroni, C, 2023) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 6.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "A significant proportion of pituitary adenomas and carcinomas had low MGMT immunoexpression." | 6.47 | Treatment of pituitary neoplasms with temozolomide: a review. ( Cusimano, M; Gonzalez, R; Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Ortiz, LD; Scheithauer, BW; Syro, LV; Uribe, H, 2011) |
| "Pituitary adenomas have relatively high expression of vascular endothelial growth factor; therefore, bevacizumab, an antiangiogenic agent, has been used in a small number of aggressive or malignant pituitary tumors after recurrence." | 5.46 | Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. ( Hoostal, S; Lou, E; Peterson, RA; SantaCruz, KS; Touma, W; Wiernik, A, 2017) |
| "Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas respond poorly to conventional therapy and cytotoxic drugs." | 5.42 | Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. ( Andersen, M; Bengtsson, D; Berinder, K; Burman, P; Feldt Rasmussen, U; Hoybye, C; Johannsson, G; Maiter, D; Petersson, M; Ragnarsson, O; Rasmussen, ÅK; Schrøder, HD; van der Lely, AJ, 2015) |
| "Pituitary carcinomas are rare and neurosurgically challenging lesions, as they commonly relapse after surgical removal." | 5.36 | SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. ( Back, W; Bode, H; Brockmann, MA; Hammes, HP; Lammert, A; Seiz, M; Thomé, C, 2010) |
| "Once temozolomide has failed, there is no recommended treatment option for pituitary carcinomas and aggressive pituitary tumors." | 5.22 | Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. ( Ilie, MD; Jouanneau, E; Raverot, G; Vasiljevic, A, 2022) |
| "A single-institution phase II trial of Temodal (temozolomide, SCH52365) in Chinese patients with advance nasopharyngeal carcinoma was undertaken to determine the efficacy and safety of the drug in this population." | 5.08 | Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma. ( Chan, AT; Johnson, PJ; Kwan, WH; Lai, M; Leung, TW; Mok, TS; Yeo, W, 1998) |
| " Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas that are resistant to other therapies." | 4.95 | Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. ( Ahmad, MM; Aldabas, BS; Aljoaib, NN; Almalki, MH; Alotaibi, MJ; Alshahrani, F; Wahedi, TS, 2017) |
| "Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas." | 4.88 | Temozolomide in aggressive pituitary adenomas and carcinomas. ( Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H, 2012) |
| "After temozolomide failure, no evidence-based treatment is available for pituitary carcinomas (PCs) and aggressive pituitary tumors (APTs)." | 4.12 | Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. ( Assie, G; Baussart, B; Cancel, M; Chanson, P; Cortet, C; Cuny, T; Decoudier, B; Deluche, E; Di Stefano, AL; Drui, D; Gaillard, S; Goichot, B; Huillard, O; Ilie, MD; Joncour, A; Larrieu-Ciron, D; Libe, R; Nars, G; Raverot, G; Vasiljevic, A; Villa, C, 2022) |
| "Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging." | 3.96 | Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. ( Bojunga, J; Buchfelder, M; Buslei, R; Deutschbein, T; Droste, M; Elbelt, U; Honegger, J; Johanssen, S; Knappe, UJ; Kolenda, H; Lammert, A; Micko, A; Petersenn, S; Ritzel, K; Schlaffer, SM; Strasburger, CJ; Topuzoglu-Müller, T; Unger, N; Vila, G, 2020) |
| "To evaluate the impact of temozolomide (TMZ) introduction on the survival of patients with pituitary carcinoma (PC) compared to aggressive pituitary adenoma (APA)." | 3.91 | Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. ( Aharon-Hananel, G; Badarna, M; Percik, R; Tirosh, A; Uri, I, 2019) |
| "To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment." | 3.88 | Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. ( Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J, 2018) |
| " Descriptions of aggressive pituitary tumors and pituitary carcinomas have increased notably over the last decade following the first report on the successful treatment of pituitary carcinomas using temozolomide." | 3.83 | Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. ( Lasolle, H; Raverot, G, 2016) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 3.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment." | 3.77 | A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. ( Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K, 2011) |
| "Prolonged administration of adjuvant temozolomide is safe and can be favorable for patients with anaplastic gliomas." | 3.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "MGMT promoter hypermethylation of aggressive pituitary adenomas and pituitary carcinomas and low protein expression are implicated in improved response to treatment with temozolomide (TMZ)." | 3.77 | MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. ( Erickson, D; Fealey, M; Horvath, E; Kovacs, K; Kros, JM; Lau, Q; Lloyd, RV; Salehi, F; Scheithauer, BW, 2011) |
| "Eight patients, five with pituitary carcinomas (three prolactin (PRL) and two ACTH) and three with aggressive pituitary tumors (one PRL and two ACTH), all treated with temozolomide administered orally for four to 24 cycles, were included in our French multicenter study." | 3.76 | Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. ( Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J, 2010) |
| "Temozolomide treatment has a wide range of efficacy in patients with pituitary carcinoma or locally aggressive pituitary adenoma." | 3.76 | Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. ( Cangi, MG; Gill, AJ; Losa, M; Mazza, E; McCormack, A; Mortini, P; Motta, M; Reni, M; Talarico, A; Terreni, MR, 2010) |
| " These studies evaluated the antitumor efficacy of CEP-7055 using orthotopic models of glioblastoma and colon carcinoma in combination with temozolomide, and irinotecan and oxaliplatin, respectively, for their effects on primary and metastatic tumor burden and median survival." | 3.73 | The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. ( Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H, 2006) |
| "Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary tumors." | 3.01 | Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. ( Barbot, M; Bergo, E; Caccese, M; Ceccato, F; Cerretti, G; Lombardi, G; Occhi, G; Padovan, M; Scaroni, C, 2023) |
| "Pituitary tumors are generally benign, although in rare cases aggressive pituitary tumors (APTs) and carcinomas present important diagnostic and therapeutic challenges and are associated with a high mortality rate." | 2.82 | Aggressive corticotroph tumors and carcinomas. ( Ilie, MD; Jouanneau, E; Lasolle, H; Raverot, G; Vasiljevic, A, 2022) |
| "Cushing's disease is a syndromic pathological condition caused by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (ACTHomas) mediated by hypercortisolemia." | 2.72 | Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. ( Fukuoka, H; Nakao, T; Ogawa, W; Yamamoto, M, 2021) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 2.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "A significant proportion of pituitary adenomas and carcinomas had low MGMT immunoexpression." | 2.47 | Treatment of pituitary neoplasms with temozolomide: a review. ( Cusimano, M; Gonzalez, R; Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Ortiz, LD; Scheithauer, BW; Syro, LV; Uribe, H, 2011) |
| "The majority of anterior pituitary tumors behave benignly, that is, they grow slowly and do not metastasize, and were therefore called adenomas." | 1.91 | Aggressive pituitary tumors (PitNETs). ( Nishioka, H, 2023) |
| "Temozolomide treatment in 156/171 patients resulted in complete response in 9." | 1.72 | Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. ( Burman, P; Dekkers, OM; Losa, M; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Theodoropoulou, M; Trouillas, J, 2022) |
| "Pituitary adenomas have relatively high expression of vascular endothelial growth factor; therefore, bevacizumab, an antiangiogenic agent, has been used in a small number of aggressive or malignant pituitary tumors after recurrence." | 1.46 | Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. ( Hoostal, S; Lou, E; Peterson, RA; SantaCruz, KS; Touma, W; Wiernik, A, 2017) |
| "Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas respond poorly to conventional therapy and cytotoxic drugs." | 1.42 | Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. ( Andersen, M; Bengtsson, D; Berinder, K; Burman, P; Feldt Rasmussen, U; Hoybye, C; Johannsson, G; Maiter, D; Petersson, M; Ragnarsson, O; Rasmussen, ÅK; Schrøder, HD; van der Lely, AJ, 2015) |
| "Nasopharyngeal carcinoma is a rare but highly invasive cancer." | 1.39 | PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. ( Chen, H; Cheung, F; Chow, JP; Li Lung, M; Man, WY; Mao, M; Nicholls, J; Poon, RY; Tsao, SW, 2013) |
| "Most drugs used for colorectal cancer therapy induce DNA-alkylation damage, which is primarily repaired by the base excision repair (BER) pathway." | 1.37 | DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer. ( Aneja, R; Banerjee, S; Jaiswal, AS; Narayan, S; Ostrov, DA; Sarkar, FH, 2011) |
| "Pituitary carcinomas are rare and neurosurgically challenging lesions, as they commonly relapse after surgical removal." | 1.36 | SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. ( Back, W; Bode, H; Brockmann, MA; Hammes, HP; Lammert, A; Seiz, M; Thomé, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.70) | 18.2507 |
| 2000's | 5 (13.51) | 29.6817 |
| 2010's | 21 (56.76) | 24.3611 |
| 2020's | 10 (27.03) | 2.80 |
| Authors | Studies |
|---|---|
| Ilie, MD | 3 |
| Vasiljevic, A | 4 |
| Jouanneau, E | 4 |
| Raverot, G | 9 |
| Lasolle, H | 3 |
| Burman, P | 4 |
| Trouillas, J | 4 |
| Losa, M | 4 |
| McCormack, A | 4 |
| Petersenn, S | 4 |
| Popovic, V | 3 |
| Theodoropoulou, M | 2 |
| Dekkers, OM | 3 |
| Villa, C | 2 |
| Cuny, T | 1 |
| Cortet, C | 2 |
| Assie, G | 2 |
| Baussart, B | 1 |
| Cancel, M | 1 |
| Chanson, P | 3 |
| Decoudier, B | 1 |
| Deluche, E | 1 |
| Di Stefano, AL | 1 |
| Drui, D | 1 |
| Gaillard, S | 3 |
| Goichot, B | 1 |
| Huillard, O | 1 |
| Joncour, A | 1 |
| Larrieu-Ciron, D | 1 |
| Libe, R | 1 |
| Nars, G | 1 |
| Nishioka, H | 1 |
| Padovan, M | 1 |
| Cerretti, G | 1 |
| Caccese, M | 1 |
| Barbot, M | 2 |
| Bergo, E | 1 |
| Occhi, G | 1 |
| Scaroni, C | 2 |
| Lombardi, G | 2 |
| Ceccato, F | 2 |
| Elbelt, U | 1 |
| Schlaffer, SM | 1 |
| Buchfelder, M | 1 |
| Knappe, UJ | 1 |
| Vila, G | 1 |
| Micko, A | 1 |
| Deutschbein, T | 1 |
| Unger, N | 1 |
| Lammert, A | 2 |
| Topuzoglu-Müller, T | 1 |
| Bojunga, J | 1 |
| Droste, M | 1 |
| Johanssen, S | 1 |
| Kolenda, H | 1 |
| Ritzel, K | 1 |
| Buslei, R | 1 |
| Strasburger, CJ | 1 |
| Honegger, J | 1 |
| Lizzul, L | 1 |
| Gardiman, MP | 1 |
| Regazzo, D | 1 |
| Bellu, L | 1 |
| Mazza, E | 2 |
| Yamamoto, M | 1 |
| Nakao, T | 1 |
| Ogawa, W | 1 |
| Fukuoka, H | 1 |
| Castinetti, F | 2 |
| Cloix, L | 1 |
| Caron, P | 2 |
| Delemer, B | 1 |
| Desailloud, R | 1 |
| Jublanc, C | 1 |
| Lebrun-Frenay, C | 1 |
| Sadoul, JL | 1 |
| Taillandier, L | 1 |
| Batisse-Lignier, M | 1 |
| Bonnet, F | 1 |
| Bourcigaux, N | 1 |
| Bresson, D | 1 |
| Chabre, O | 2 |
| Garcia, C | 1 |
| Haissaguerre, M | 1 |
| Reznik, Y | 1 |
| Borot, S | 1 |
| Almalki, MH | 1 |
| Aljoaib, NN | 1 |
| Alotaibi, MJ | 1 |
| Aldabas, BS | 1 |
| Wahedi, TS | 1 |
| Ahmad, MM | 1 |
| Alshahrani, F | 1 |
| Aharon-Hananel, G | 1 |
| Percik, R | 1 |
| Badarna, M | 1 |
| Uri, I | 1 |
| Tirosh, A | 1 |
| Chow, JP | 1 |
| Man, WY | 1 |
| Mao, M | 1 |
| Chen, H | 1 |
| Cheung, F | 1 |
| Nicholls, J | 1 |
| Tsao, SW | 1 |
| Li Lung, M | 1 |
| Poon, RY | 1 |
| Minniti, G | 1 |
| Scaringi, C | 1 |
| Lanzetta, G | 1 |
| Bozzao, A | 1 |
| Romano, A | 1 |
| De Sanctis, V | 1 |
| Valeriani, M | 1 |
| Osti, M | 1 |
| Enrici, RM | 1 |
| Bengtsson, D | 1 |
| Schrøder, HD | 1 |
| Andersen, M | 1 |
| Maiter, D | 1 |
| Berinder, K | 1 |
| Feldt Rasmussen, U | 1 |
| Rasmussen, ÅK | 1 |
| Johannsson, G | 1 |
| Hoybye, C | 1 |
| van der Lely, AJ | 1 |
| Petersson, M | 1 |
| Ragnarsson, O | 1 |
| Chen, TC | 1 |
| Cho, HY | 1 |
| Wang, W | 1 |
| Wetzel, SJ | 1 |
| Singh, A | 1 |
| Nguyen, J | 1 |
| Hofman, FM | 1 |
| Schönthal, AH | 1 |
| Touma, W | 1 |
| Hoostal, S | 1 |
| Peterson, RA | 1 |
| Wiernik, A | 1 |
| SantaCruz, KS | 1 |
| Lou, E | 1 |
| Lozier, AP | 1 |
| Arbaje, YM | 1 |
| Scheithauer, BW | 4 |
| Bode, H | 1 |
| Seiz, M | 2 |
| Brockmann, MA | 1 |
| Back, W | 1 |
| Hammes, HP | 1 |
| Thomé, C | 2 |
| Sturm, N | 1 |
| de Fraipont, F | 1 |
| Muller, M | 1 |
| Salenave, S | 1 |
| Cortet-Rudelli, C | 1 |
| Assaker, R | 1 |
| Dufour, H | 2 |
| François, P | 1 |
| Passagia, JG | 1 |
| Bernier, M | 1 |
| Cornélius, A | 1 |
| Figarella-Branger, D | 1 |
| Borson-Chazot, F | 1 |
| Brue, T | 2 |
| Syro, LV | 2 |
| Ortiz, LD | 2 |
| Lloyd, R | 1 |
| Lau, Q | 2 |
| Gonzalez, R | 1 |
| Uribe, H | 2 |
| Cusimano, M | 1 |
| Kovacs, K | 3 |
| Horvath, E | 3 |
| Terreni, MR | 1 |
| Gill, AJ | 1 |
| Motta, M | 1 |
| Cangi, MG | 1 |
| Talarico, A | 1 |
| Mortini, P | 1 |
| Reni, M | 1 |
| Jaiswal, AS | 1 |
| Banerjee, S | 1 |
| Aneja, R | 1 |
| Sarkar, FH | 1 |
| Ostrov, DA | 1 |
| Narayan, S | 1 |
| Salehi, F | 1 |
| Kros, JM | 1 |
| Fealey, M | 1 |
| Erickson, D | 1 |
| Lloyd, RV | 1 |
| Murakami, M | 1 |
| Mizutani, A | 1 |
| Asano, S | 1 |
| Katakami, H | 1 |
| Ozawa, Y | 1 |
| Yamazaki, K | 1 |
| Ishida, Y | 1 |
| Takano, K | 1 |
| Okinaga, H | 1 |
| Matsuno, A | 1 |
| Freyschlag, CF | 1 |
| Smolczyk, DR | 1 |
| Janzen, E | 1 |
| Schmieder, K | 1 |
| Lohr, F | 1 |
| Wenz, F | 1 |
| Weiss, C | 1 |
| Tuettenberg, J | 1 |
| Philippon, M | 1 |
| Morange, I | 1 |
| Barrie, M | 1 |
| Barlier, A | 1 |
| Taieb, D | 1 |
| Conte-Devolx, B | 1 |
| Rotondo, F | 1 |
| Fadul, CE | 1 |
| Dixit, S | 1 |
| Salvage, D | 1 |
| Rajaraman, C | 1 |
| Hingorani, M | 1 |
| Rowland-Hill, C | 1 |
| Lim, S | 1 |
| Shahinian, H | 1 |
| Maya, MM | 1 |
| Yong, W | 1 |
| Heaney, AP | 1 |
| Jones-Bolin, S | 1 |
| Zhao, H | 1 |
| Hunter, K | 1 |
| Klein-Szanto, A | 1 |
| Ruggeri, B | 1 |
| Siker, ML | 1 |
| Chakravarti, A | 1 |
| Mehta, MP | 1 |
| Caporali, S | 1 |
| Levati, L | 1 |
| Starace, G | 1 |
| Ragone, G | 1 |
| Bonmassar, E | 1 |
| Alvino, E | 1 |
| D'Atri, S | 1 |
| Chan, AT | 1 |
| Leung, TW | 1 |
| Kwan, WH | 1 |
| Mok, TS | 1 |
| Yeo, W | 1 |
| Lai, M | 1 |
| Johnson, PJ | 1 |
9 reviews available for temozolomide and Carcinoma
| Article | Year |
|---|---|
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review.
Topics: Carcinoma; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Pituitary Neoplasms; Temozolomide | 2022 |
Aggressive corticotroph tumors and carcinomas.
Topics: Adenoma; Carcinoma; Corticotrophs; Humans; Pituitary Neoplasms; Temozolomide | 2022 |
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Tem | 2023 |
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma | 2020 |
Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Carcinoma; Dopamine Agonists | 2021 |
Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Prolactinoma | 2017 |
Treatment of pituitary neoplasms with temozolomide: a review.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinoma; Dacarbazine; DNA Modificat | 2011 |
Temozolomide in aggressive pituitary adenomas and carcinomas.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Tem | 2012 |
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Chemotherapy, Adjuvant; | 2006 |
2 trials available for temozolomide and Carcinoma
| Article | Year |
|---|---|
Whole brain reirradiation and concurrent temozolomide in patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcin | 2014 |
Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Female; Humans; Male; Middle | 1998 |
26 other studies available for temozolomide and Carcinoma
| Article | Year |
|---|---|
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
Topics: Adenoma; Adrenocorticotropic Hormone; Bevacizumab; Carcinoma; Female; Humans; Immune Checkpoint Inhi | 2022 |
Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Topics: B7-H1 Antigen; Carcinoma; Cohort Studies; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Pitui | 2022 |
Aggressive pituitary tumors (PitNETs).
Topics: Adenoma; Carcinoma; Humans; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide | 2023 |
Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?-that is the question.
Topics: Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Topics: Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Female; Germany; Humans; Male; Middle | 2020 |
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Chemoradiothe | 2017 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2018 |
Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.
Topics: Adenoma; Aged; Antineoplastic Agents, Alkylating; Carcinoma; Female; Humans; Israel; Male; Middle Ag | 2019 |
PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Cell Proliferation; Combined Moda | 2013 |
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Bi | 2015 |
Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo.
Topics: Animals; Carcinoma; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Mice; Mice | 2015 |
Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Forecasting; Humans; Pituitary Neoplasms; | 2016 |
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2017 |
Supratentorial, extraventricular choroid plexus carcinoma in an adult: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Carcinoma; Choroid Plexus; Choroid Plexus Neoplasms; | 2009 |
SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Ant | 2010 |
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; | 2010 |
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Female; Humans; Male; Middle Age | 2010 |
DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Carcin | 2011 |
MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
Topics: Adenoma; Adolescent; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; DNA Methylati | 2011 |
A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Cell Transformation, Neoplastic; Dacarbazine; DNA Modi | 2011 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine | 2012 |
Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma; Carcinoma, Papillary; Dacarbazine | 2013 |
Temozolomide: a novel treatment for pituitary carcinoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma; Combined Modality Therapy; Dacarbazine; Humans; | 2006 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazo | 2006 |
AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; B-Lymphocytes; Breast Neo | 2008 |